Infrarenal Aortic Stenosis Management
For infrarenal aortic stenosis in older adults with atherosclerotic risk factors, endovascular stenting is the first-line treatment for symptomatic patients, combined with aggressive medical therapy including antiplatelet agents, high-intensity statins, and optimal blood pressure control.
Medical Management (Foundation for All Patients)
All patients with infrarenal aortic stenosis require comprehensive medical therapy regardless of whether they undergo intervention 1, 2, 3:
- Antiplatelet therapy: Aspirin or clopidogrel
- High-intensity statin: For atherosclerotic disease management
- Blood pressure control: Target <140/90 mmHg (or <130/80 mmHg if diabetes present) 4, 1
- Smoking cessation: Critical, as smoking is the dominant risk factor in this population
- ACE inhibitor or ARB: Particularly beneficial for concurrent hypertension or renal protection 4, 3
Indications for Endovascular Intervention
Proceed with endovascular stenting when patients have:
- Symptomatic disease (claudication, rest pain, or tissue loss)
- Hemodynamically significant stenosis (typically ≥70%)
- Adequate anatomy for endovascular approach
The evidence strongly supports endovascular treatment as first-line therapy. Studies demonstrate 88-100% primary patency at 5 years with stenting 5, 6, 7. Technical success exceeds 90%, with minimal complications 8, 5.
Endovascular Technique Specifics
Stenting is preferred over balloon angioplasty alone 8, 5, 6:
- Self-expanding stents are the standard approach
- Primary stenting (without pre-dilation) may reduce thromboembolic complications
- Direct stenting achieves immediate technical success in >95% of cases
Key Technical Considerations:
- Median lesion length treated: 13-30 mm
- Stenosis grade typically 70-80%
- Severe calcification present in only 8% of cases 5
Complications and Management
Thromboembolic complications are the primary concern, occurring in up to 10-15% of cases 8:
- Treat with catheter-directed thrombolysis or anticoagulation
- Most resolve without permanent sequelae
- Access-site complications are rare (5-6%) 6
Critical complication: Aortic rupture is extremely rare (<3%) but requires immediate surgical conversion 5.
Long-Term Outcomes and Surveillance
Primary patency rates are excellent 5, 6, 7:
- 97-100% at 1 year
- 88-90% at 5 years
- 77-83% at 5 years (primary assisted patency)
Restenosis occurs in only 5-8% of patients and typically presents late (>6 years post-procedure) 5, 6. When symptoms recur, they are more commonly due to:
- Disease progression in distal vessels (iliac/femoral arteries)
- Progression in non-stented aortic segments
- Not in-stent restenosis
Follow-Up Protocol
Structured surveillance is essential:
- Clinical assessment at 1,6, and 12 months, then annually
- Color Doppler ultrasound at each visit
- CT angiography if ultrasound suggests restenosis
- Monitor ankle-brachial index (expect improvement from ~0.63 to >0.95) 9
Patient Selection Pearls
This condition predominantly affects young to middle-aged women who are heavy smokers (64% female, median age 55-62 years) 9, 5, 7. The atherosclerotic process is typically confined to the infrarenal aorta, making it ideal for focal endovascular treatment.
Contraindications to endovascular approach:
- Extensive calcification preventing stent deployment
- Lesion length >6 cm
- Concurrent need for open aortic surgery (aneurysm repair)
In these rare cases, surgical thrombendarterectomy remains an option, though endovascular failure can still be salvaged surgically 6, 7.
Why Endovascular Over Surgery
The evidence decisively favors endovascular treatment 8, 9, 5, 6, 7:
- Minimally invasive with faster recovery
- Equivalent or superior long-term patency compared to historical surgical series
- Lower perioperative morbidity
- Repeatable if restenosis occurs (unlike surgical revision)
- Particularly advantageous in this relatively young patient population who may need future interventions
Bottom line: Endovascular stenting combined with aggressive medical therapy provides durable symptom relief with excellent long-term patency and low complication rates, making it the clear first-choice treatment for symptomatic infrarenal aortic stenosis.